Onset of eosinophilic esophagitis during a clinical trial program of oral immunotherapy for peanut allergy
In this analysis of the PTAH clinical trial program, the overall incidence of EoE was approximately 1%, which is lower than previously reported rates of EoE with OIT for food allergies (2.7% in a meta-analysis and 5.1% in a recent retrospective review).1,6 The etiology of EoE pathogenesis in the cas...
Gespeichert in:
Veröffentlicht in: | The journal of allergy and clinical immunology in practice (Cambridge, MA) MA), 2021-12, Vol.9 (12), p.4496-4501 |
---|---|
Hauptverfasser: | , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 4501 |
---|---|
container_issue | 12 |
container_start_page | 4496 |
container_title | The journal of allergy and clinical immunology in practice (Cambridge, MA) |
container_volume | 9 |
creator | Nilsson, Caroline Scurlock, Amy M. Dellon, Evan S. Brostoff, Joshua M. Pham, Trinh Ryan, Robert Brown, Kari R. Adelman, Daniel C. Aceves, Seema S. |
description | In this analysis of the PTAH clinical trial program, the overall incidence of EoE was approximately 1%, which is lower than previously reported rates of EoE with OIT for food allergies (2.7% in a meta-analysis and 5.1% in a recent retrospective review).1,6 The etiology of EoE pathogenesis in the cases reported in the PTAH clinical trial program is not definitively known, but may include EoE present and not diagnosed before OIT, EoE pre-existing but subclinical and exacerbated by OIT, or EoE triggered de novo by OIT. In a recent longitudinal placebo-controlled study examining serial endoscopic biopsies during peanut OIT, all the peanut-allergic participants had signs of epithelial barrier dysfunction at baseline and in some cases esophageal eosinophilia.8 The study demonstrated that most OIT-associated esophageal eosinophilia resolves during maintenance OIT and is not associated with clinical symptoms. Because the majority of participants in the PTAH clinical trials stopped the study drug around the time of EoE diagnosis, it is not known whether the eosinophilic infiltrate would have resolved with continued dosing. [...]the rate of developing EoE with PTAH in this clinical trial program was approximately 1%, not including the 5% of participants who discontinued PTAH treatment because of GI adverse events that were not further evaluated. Relevant medical history PTAH dose at EoE diagnosis (mg) Total exposure to PTAH (d) Symptoms Severity∗ Initial esophageal biopsy results Repeat esophageal biopsy results† Treatment Relatedness to PTAH∗ At first GI symptom onset At EoE diagnosis 1 12 58 58 Intermittent vomiting, abdominal pain, sore throat Mild EoE with peak eosinophil count of 92 eos/hpf Biopsy performed—results NA‡ Esomeprazole for vomiting; swallowed fluticasone after EoE diagnosis, elimination diet Related 2 Gastroesophageal reflux during infancy and chronic regurgitation 950§ 58 428 Frequent regurgitating/spitting up, gastric reflux Moderate The peak eosinophil count was 32 eos/hpf in the distal esophagus, 7 eos/hpf in the mid-esophagus, and up to 61 eos/hpf in the proximal esophagus NR Ranitidine, omeprazole, lansoprazole Related 3 Gastroesophageal reflux; recurrent nausea and cough 200 30 176 Gastroesophageal reflux, |
doi_str_mv | 10.1016/j.jaip.2021.07.048 |
format | Article |
fullrecord | <record><control><sourceid>proquest_swepu</sourceid><recordid>TN_cdi_swepub_primary_oai_swepub_ki_se_459818</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S2213219821008898</els_id><sourcerecordid>2561487296</sourcerecordid><originalsourceid>FETCH-LOGICAL-c466t-6aa58f33d1ea84150e34c2d0a8b61e0c3572c5496ec6c0ddcf4165d9598cc0873</originalsourceid><addsrcrecordid>eNp9kc1u1DAUha0K1FalL8ACWWLDJsH_cSQ2qKJQqVI3sLY8zs3UIbGDnYDm7etopl2wqBf2sfWdq3t9EHpPSU0JVZ-HerB-rhlhtCZNTYQ-Q5eMUV4xRuibZ01bfYGucx5IWZo2RJBzdMEF160k4hINDyHDgmOPIWYf4vzoR-8w5KLs3i8-425NPuyxxW70wTs74iX5ss8p7pOdNm9M5e6naQ1xeYRk5wPuY8Iz2LAu2I4jpP3hHXrb2zHD9em8Qr9uv_28-VHdP3y_u_l6Xzmh1FIpa6XuOe8oWC2oJMCFYx2xeqcoEMdlw5wUrQKnHOk61wuqZNfKVjtHdMOvUHWsm__BvO7MnPxk08FE683p6XdRYESxUF34T0e-DPRnhbyYyWcH42gDxDUbJhUVumGtKujH_9AhrimUaQxTpOFUNnqj2JFyKeacoH9pgRKzhWcGs4VntvAMaUwJr5g-nEqvuwm6F8tzVAX4cgSg_N1fD8lk5yE46HwCt5gu-tfqPwEHpKv3</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2607315786</pqid></control><display><type>article</type><title>Onset of eosinophilic esophagitis during a clinical trial program of oral immunotherapy for peanut allergy</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><source>SWEPUB Freely available online</source><creator>Nilsson, Caroline ; Scurlock, Amy M. ; Dellon, Evan S. ; Brostoff, Joshua M. ; Pham, Trinh ; Ryan, Robert ; Brown, Kari R. ; Adelman, Daniel C. ; Aceves, Seema S.</creator><creatorcontrib>Nilsson, Caroline ; Scurlock, Amy M. ; Dellon, Evan S. ; Brostoff, Joshua M. ; Pham, Trinh ; Ryan, Robert ; Brown, Kari R. ; Adelman, Daniel C. ; Aceves, Seema S.</creatorcontrib><description>In this analysis of the PTAH clinical trial program, the overall incidence of EoE was approximately 1%, which is lower than previously reported rates of EoE with OIT for food allergies (2.7% in a meta-analysis and 5.1% in a recent retrospective review).1,6 The etiology of EoE pathogenesis in the cases reported in the PTAH clinical trial program is not definitively known, but may include EoE present and not diagnosed before OIT, EoE pre-existing but subclinical and exacerbated by OIT, or EoE triggered de novo by OIT. In a recent longitudinal placebo-controlled study examining serial endoscopic biopsies during peanut OIT, all the peanut-allergic participants had signs of epithelial barrier dysfunction at baseline and in some cases esophageal eosinophilia.8 The study demonstrated that most OIT-associated esophageal eosinophilia resolves during maintenance OIT and is not associated with clinical symptoms. Because the majority of participants in the PTAH clinical trials stopped the study drug around the time of EoE diagnosis, it is not known whether the eosinophilic infiltrate would have resolved with continued dosing. [...]the rate of developing EoE with PTAH in this clinical trial program was approximately 1%, not including the 5% of participants who discontinued PTAH treatment because of GI adverse events that were not further evaluated. Relevant medical history PTAH dose at EoE diagnosis (mg) Total exposure to PTAH (d) Symptoms Severity∗ Initial esophageal biopsy results Repeat esophageal biopsy results† Treatment Relatedness to PTAH∗ At first GI symptom onset At EoE diagnosis 1 12 58 58 Intermittent vomiting, abdominal pain, sore throat Mild EoE with peak eosinophil count of 92 eos/hpf Biopsy performed—results NA‡ Esomeprazole for vomiting; swallowed fluticasone after EoE diagnosis, elimination diet Related 2 Gastroesophageal reflux during infancy and chronic regurgitation 950§ 58 428 Frequent regurgitating/spitting up, gastric reflux Moderate The peak eosinophil count was 32 eos/hpf in the distal esophagus, 7 eos/hpf in the mid-esophagus, and up to 61 eos/hpf in the proximal esophagus NR Ranitidine, omeprazole, lansoprazole Related 3 Gastroesophageal reflux; recurrent nausea and cough 200 30 176 Gastroesophageal reflux,</description><identifier>ISSN: 2213-2198</identifier><identifier>EISSN: 2213-2201</identifier><identifier>DOI: 10.1016/j.jaip.2021.07.048</identifier><identifier>PMID: 34389504</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Administration, Oral ; Adverse events ; Allergens ; Allergies ; Arachis ; Asthma ; Autoimmune diseases ; Biopsy ; Clinical trials ; Comorbidity ; Cough ; Dermatitis ; Desensitization, Immunologic ; Diagnosis ; Disease ; Dosage ; Drug dosages ; Endoscopy ; Enteritis ; Eosinophilia ; Eosinophilic Esophagitis - therapy ; Esophageal diseases ; Esophagitis ; Esophagus ; Etiology ; Fluticasone ; Food allergies ; Gastritis ; Gastroenterology ; Gastroesophageal reflux ; Gastrointestinal diseases ; Humans ; Immunotherapy ; Leukocytes (eosinophilic) ; Meta-analysis ; Nausea ; Omeprazole ; Peanut Hypersensitivity - therapy ; Pharyngitis ; Ranitidine ; Regurgitation ; Rhinitis ; Vomiting</subject><ispartof>The journal of allergy and clinical immunology in practice (Cambridge, MA), 2021-12, Vol.9 (12), p.4496-4501</ispartof><rights>2021 The Authors</rights><rights>2021. The Authors</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c466t-6aa58f33d1ea84150e34c2d0a8b61e0c3572c5496ec6c0ddcf4165d9598cc0873</citedby><cites>FETCH-LOGICAL-c466t-6aa58f33d1ea84150e34c2d0a8b61e0c3572c5496ec6c0ddcf4165d9598cc0873</cites><orcidid>0000-0003-0827-3153</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,550,776,780,881,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34389504$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttp://kipublications.ki.se/Default.aspx?queryparsed=id:148340040$$DView record from Swedish Publication Index$$Hfree_for_read</backlink></links><search><creatorcontrib>Nilsson, Caroline</creatorcontrib><creatorcontrib>Scurlock, Amy M.</creatorcontrib><creatorcontrib>Dellon, Evan S.</creatorcontrib><creatorcontrib>Brostoff, Joshua M.</creatorcontrib><creatorcontrib>Pham, Trinh</creatorcontrib><creatorcontrib>Ryan, Robert</creatorcontrib><creatorcontrib>Brown, Kari R.</creatorcontrib><creatorcontrib>Adelman, Daniel C.</creatorcontrib><creatorcontrib>Aceves, Seema S.</creatorcontrib><title>Onset of eosinophilic esophagitis during a clinical trial program of oral immunotherapy for peanut allergy</title><title>The journal of allergy and clinical immunology in practice (Cambridge, MA)</title><addtitle>J Allergy Clin Immunol Pract</addtitle><description>In this analysis of the PTAH clinical trial program, the overall incidence of EoE was approximately 1%, which is lower than previously reported rates of EoE with OIT for food allergies (2.7% in a meta-analysis and 5.1% in a recent retrospective review).1,6 The etiology of EoE pathogenesis in the cases reported in the PTAH clinical trial program is not definitively known, but may include EoE present and not diagnosed before OIT, EoE pre-existing but subclinical and exacerbated by OIT, or EoE triggered de novo by OIT. In a recent longitudinal placebo-controlled study examining serial endoscopic biopsies during peanut OIT, all the peanut-allergic participants had signs of epithelial barrier dysfunction at baseline and in some cases esophageal eosinophilia.8 The study demonstrated that most OIT-associated esophageal eosinophilia resolves during maintenance OIT and is not associated with clinical symptoms. Because the majority of participants in the PTAH clinical trials stopped the study drug around the time of EoE diagnosis, it is not known whether the eosinophilic infiltrate would have resolved with continued dosing. [...]the rate of developing EoE with PTAH in this clinical trial program was approximately 1%, not including the 5% of participants who discontinued PTAH treatment because of GI adverse events that were not further evaluated. Relevant medical history PTAH dose at EoE diagnosis (mg) Total exposure to PTAH (d) Symptoms Severity∗ Initial esophageal biopsy results Repeat esophageal biopsy results† Treatment Relatedness to PTAH∗ At first GI symptom onset At EoE diagnosis 1 12 58 58 Intermittent vomiting, abdominal pain, sore throat Mild EoE with peak eosinophil count of 92 eos/hpf Biopsy performed—results NA‡ Esomeprazole for vomiting; swallowed fluticasone after EoE diagnosis, elimination diet Related 2 Gastroesophageal reflux during infancy and chronic regurgitation 950§ 58 428 Frequent regurgitating/spitting up, gastric reflux Moderate The peak eosinophil count was 32 eos/hpf in the distal esophagus, 7 eos/hpf in the mid-esophagus, and up to 61 eos/hpf in the proximal esophagus NR Ranitidine, omeprazole, lansoprazole Related 3 Gastroesophageal reflux; recurrent nausea and cough 200 30 176 Gastroesophageal reflux,</description><subject>Administration, Oral</subject><subject>Adverse events</subject><subject>Allergens</subject><subject>Allergies</subject><subject>Arachis</subject><subject>Asthma</subject><subject>Autoimmune diseases</subject><subject>Biopsy</subject><subject>Clinical trials</subject><subject>Comorbidity</subject><subject>Cough</subject><subject>Dermatitis</subject><subject>Desensitization, Immunologic</subject><subject>Diagnosis</subject><subject>Disease</subject><subject>Dosage</subject><subject>Drug dosages</subject><subject>Endoscopy</subject><subject>Enteritis</subject><subject>Eosinophilia</subject><subject>Eosinophilic Esophagitis - therapy</subject><subject>Esophageal diseases</subject><subject>Esophagitis</subject><subject>Esophagus</subject><subject>Etiology</subject><subject>Fluticasone</subject><subject>Food allergies</subject><subject>Gastritis</subject><subject>Gastroenterology</subject><subject>Gastroesophageal reflux</subject><subject>Gastrointestinal diseases</subject><subject>Humans</subject><subject>Immunotherapy</subject><subject>Leukocytes (eosinophilic)</subject><subject>Meta-analysis</subject><subject>Nausea</subject><subject>Omeprazole</subject><subject>Peanut Hypersensitivity - therapy</subject><subject>Pharyngitis</subject><subject>Ranitidine</subject><subject>Regurgitation</subject><subject>Rhinitis</subject><subject>Vomiting</subject><issn>2213-2198</issn><issn>2213-2201</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>D8T</sourceid><recordid>eNp9kc1u1DAUha0K1FalL8ACWWLDJsH_cSQ2qKJQqVI3sLY8zs3UIbGDnYDm7etopl2wqBf2sfWdq3t9EHpPSU0JVZ-HerB-rhlhtCZNTYQ-Q5eMUV4xRuibZ01bfYGucx5IWZo2RJBzdMEF160k4hINDyHDgmOPIWYf4vzoR-8w5KLs3i8-425NPuyxxW70wTs74iX5ss8p7pOdNm9M5e6naQ1xeYRk5wPuY8Iz2LAu2I4jpP3hHXrb2zHD9em8Qr9uv_28-VHdP3y_u_l6Xzmh1FIpa6XuOe8oWC2oJMCFYx2xeqcoEMdlw5wUrQKnHOk61wuqZNfKVjtHdMOvUHWsm__BvO7MnPxk08FE683p6XdRYESxUF34T0e-DPRnhbyYyWcH42gDxDUbJhUVumGtKujH_9AhrimUaQxTpOFUNnqj2JFyKeacoH9pgRKzhWcGs4VntvAMaUwJr5g-nEqvuwm6F8tzVAX4cgSg_N1fD8lk5yE46HwCt5gu-tfqPwEHpKv3</recordid><startdate>20211201</startdate><enddate>20211201</enddate><creator>Nilsson, Caroline</creator><creator>Scurlock, Amy M.</creator><creator>Dellon, Evan S.</creator><creator>Brostoff, Joshua M.</creator><creator>Pham, Trinh</creator><creator>Ryan, Robert</creator><creator>Brown, Kari R.</creator><creator>Adelman, Daniel C.</creator><creator>Aceves, Seema S.</creator><general>Elsevier Inc</general><general>Elsevier Limited</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope><scope>ADTPV</scope><scope>AOWAS</scope><scope>D8T</scope><scope>ZZAVC</scope><orcidid>https://orcid.org/0000-0003-0827-3153</orcidid></search><sort><creationdate>20211201</creationdate><title>Onset of eosinophilic esophagitis during a clinical trial program of oral immunotherapy for peanut allergy</title><author>Nilsson, Caroline ; Scurlock, Amy M. ; Dellon, Evan S. ; Brostoff, Joshua M. ; Pham, Trinh ; Ryan, Robert ; Brown, Kari R. ; Adelman, Daniel C. ; Aceves, Seema S.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c466t-6aa58f33d1ea84150e34c2d0a8b61e0c3572c5496ec6c0ddcf4165d9598cc0873</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Administration, Oral</topic><topic>Adverse events</topic><topic>Allergens</topic><topic>Allergies</topic><topic>Arachis</topic><topic>Asthma</topic><topic>Autoimmune diseases</topic><topic>Biopsy</topic><topic>Clinical trials</topic><topic>Comorbidity</topic><topic>Cough</topic><topic>Dermatitis</topic><topic>Desensitization, Immunologic</topic><topic>Diagnosis</topic><topic>Disease</topic><topic>Dosage</topic><topic>Drug dosages</topic><topic>Endoscopy</topic><topic>Enteritis</topic><topic>Eosinophilia</topic><topic>Eosinophilic Esophagitis - therapy</topic><topic>Esophageal diseases</topic><topic>Esophagitis</topic><topic>Esophagus</topic><topic>Etiology</topic><topic>Fluticasone</topic><topic>Food allergies</topic><topic>Gastritis</topic><topic>Gastroenterology</topic><topic>Gastroesophageal reflux</topic><topic>Gastrointestinal diseases</topic><topic>Humans</topic><topic>Immunotherapy</topic><topic>Leukocytes (eosinophilic)</topic><topic>Meta-analysis</topic><topic>Nausea</topic><topic>Omeprazole</topic><topic>Peanut Hypersensitivity - therapy</topic><topic>Pharyngitis</topic><topic>Ranitidine</topic><topic>Regurgitation</topic><topic>Rhinitis</topic><topic>Vomiting</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Nilsson, Caroline</creatorcontrib><creatorcontrib>Scurlock, Amy M.</creatorcontrib><creatorcontrib>Dellon, Evan S.</creatorcontrib><creatorcontrib>Brostoff, Joshua M.</creatorcontrib><creatorcontrib>Pham, Trinh</creatorcontrib><creatorcontrib>Ryan, Robert</creatorcontrib><creatorcontrib>Brown, Kari R.</creatorcontrib><creatorcontrib>Adelman, Daniel C.</creatorcontrib><creatorcontrib>Aceves, Seema S.</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><collection>SwePub</collection><collection>SwePub Articles</collection><collection>SWEPUB Freely available online</collection><collection>SwePub Articles full text</collection><jtitle>The journal of allergy and clinical immunology in practice (Cambridge, MA)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Nilsson, Caroline</au><au>Scurlock, Amy M.</au><au>Dellon, Evan S.</au><au>Brostoff, Joshua M.</au><au>Pham, Trinh</au><au>Ryan, Robert</au><au>Brown, Kari R.</au><au>Adelman, Daniel C.</au><au>Aceves, Seema S.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Onset of eosinophilic esophagitis during a clinical trial program of oral immunotherapy for peanut allergy</atitle><jtitle>The journal of allergy and clinical immunology in practice (Cambridge, MA)</jtitle><addtitle>J Allergy Clin Immunol Pract</addtitle><date>2021-12-01</date><risdate>2021</risdate><volume>9</volume><issue>12</issue><spage>4496</spage><epage>4501</epage><pages>4496-4501</pages><issn>2213-2198</issn><eissn>2213-2201</eissn><abstract>In this analysis of the PTAH clinical trial program, the overall incidence of EoE was approximately 1%, which is lower than previously reported rates of EoE with OIT for food allergies (2.7% in a meta-analysis and 5.1% in a recent retrospective review).1,6 The etiology of EoE pathogenesis in the cases reported in the PTAH clinical trial program is not definitively known, but may include EoE present and not diagnosed before OIT, EoE pre-existing but subclinical and exacerbated by OIT, or EoE triggered de novo by OIT. In a recent longitudinal placebo-controlled study examining serial endoscopic biopsies during peanut OIT, all the peanut-allergic participants had signs of epithelial barrier dysfunction at baseline and in some cases esophageal eosinophilia.8 The study demonstrated that most OIT-associated esophageal eosinophilia resolves during maintenance OIT and is not associated with clinical symptoms. Because the majority of participants in the PTAH clinical trials stopped the study drug around the time of EoE diagnosis, it is not known whether the eosinophilic infiltrate would have resolved with continued dosing. [...]the rate of developing EoE with PTAH in this clinical trial program was approximately 1%, not including the 5% of participants who discontinued PTAH treatment because of GI adverse events that were not further evaluated. Relevant medical history PTAH dose at EoE diagnosis (mg) Total exposure to PTAH (d) Symptoms Severity∗ Initial esophageal biopsy results Repeat esophageal biopsy results† Treatment Relatedness to PTAH∗ At first GI symptom onset At EoE diagnosis 1 12 58 58 Intermittent vomiting, abdominal pain, sore throat Mild EoE with peak eosinophil count of 92 eos/hpf Biopsy performed—results NA‡ Esomeprazole for vomiting; swallowed fluticasone after EoE diagnosis, elimination diet Related 2 Gastroesophageal reflux during infancy and chronic regurgitation 950§ 58 428 Frequent regurgitating/spitting up, gastric reflux Moderate The peak eosinophil count was 32 eos/hpf in the distal esophagus, 7 eos/hpf in the mid-esophagus, and up to 61 eos/hpf in the proximal esophagus NR Ranitidine, omeprazole, lansoprazole Related 3 Gastroesophageal reflux; recurrent nausea and cough 200 30 176 Gastroesophageal reflux,</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>34389504</pmid><doi>10.1016/j.jaip.2021.07.048</doi><tpages>6</tpages><orcidid>https://orcid.org/0000-0003-0827-3153</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 2213-2198 |
ispartof | The journal of allergy and clinical immunology in practice (Cambridge, MA), 2021-12, Vol.9 (12), p.4496-4501 |
issn | 2213-2198 2213-2201 |
language | eng |
recordid | cdi_swepub_primary_oai_swepub_ki_se_459818 |
source | MEDLINE; Alma/SFX Local Collection; SWEPUB Freely available online |
subjects | Administration, Oral Adverse events Allergens Allergies Arachis Asthma Autoimmune diseases Biopsy Clinical trials Comorbidity Cough Dermatitis Desensitization, Immunologic Diagnosis Disease Dosage Drug dosages Endoscopy Enteritis Eosinophilia Eosinophilic Esophagitis - therapy Esophageal diseases Esophagitis Esophagus Etiology Fluticasone Food allergies Gastritis Gastroenterology Gastroesophageal reflux Gastrointestinal diseases Humans Immunotherapy Leukocytes (eosinophilic) Meta-analysis Nausea Omeprazole Peanut Hypersensitivity - therapy Pharyngitis Ranitidine Regurgitation Rhinitis Vomiting |
title | Onset of eosinophilic esophagitis during a clinical trial program of oral immunotherapy for peanut allergy |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-14T00%3A51%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_swepu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Onset%20of%20eosinophilic%20esophagitis%20during%20a%20clinical%20trial%20program%20of%20oral%20immunotherapy%20for%20peanut%20allergy&rft.jtitle=The%20journal%20of%20allergy%20and%20clinical%20immunology%20in%20practice%20(Cambridge,%20MA)&rft.au=Nilsson,%20Caroline&rft.date=2021-12-01&rft.volume=9&rft.issue=12&rft.spage=4496&rft.epage=4501&rft.pages=4496-4501&rft.issn=2213-2198&rft.eissn=2213-2201&rft_id=info:doi/10.1016/j.jaip.2021.07.048&rft_dat=%3Cproquest_swepu%3E2561487296%3C/proquest_swepu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2607315786&rft_id=info:pmid/34389504&rft_els_id=S2213219821008898&rfr_iscdi=true |